Neurix

Executive Summary

Neurix SA is a Swiss biotechnology spin-off from the University of Geneva, specializing in advanced in vitro cellular models derived from human induced pluripotent stem cells (iPSCs). Founded in 2015 and based in Basel, Neurix develops physiologically relevant systems that replicate brain physiology and pathology. These platforms aim to accelerate drug discovery and therapeutic validation for neurological diseases, addressing a critical need in a field with high failure rates in clinical trials. The company's technology holds potential to improve predictability of preclinical studies, reduce reliance on animal models, and enable personalized medicine approaches.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a major pharmaceutical company for drug screening services45% success
• Q1 2027Series A financing round to scale platform and expand operations60% success
• Q2 2026Publication of key validation data in a peer-reviewed neuroscience journal70% success